AU784630B2 - Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis - Google Patents

Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis Download PDF

Info

Publication number
AU784630B2
AU784630B2 AU21340/01A AU2134001A AU784630B2 AU 784630 B2 AU784630 B2 AU 784630B2 AU 21340/01 A AU21340/01 A AU 21340/01A AU 2134001 A AU2134001 A AU 2134001A AU 784630 B2 AU784630 B2 AU 784630B2
Authority
AU
Australia
Prior art keywords
group
leu
peptide
val
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU21340/01A
Other languages
English (en)
Other versions
AU2134001A (en
Inventor
Sylvain Chemtob
Krishna G. Peri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire Saint Justine
Original Assignee
Centre Hospitalier Universitaire Saint Justine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire Saint Justine filed Critical Centre Hospitalier Universitaire Saint Justine
Publication of AU2134001A publication Critical patent/AU2134001A/en
Application granted granted Critical
Publication of AU784630B2 publication Critical patent/AU784630B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pipe Accessories (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Joints With Sleeves (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Water Treatment By Sorption (AREA)
AU21340/01A 1999-12-06 2000-12-06 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis Ceased AU784630B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45548399A 1999-12-06 1999-12-06
US09/455483 1999-12-06
PCT/CA2000/001445 WO2001042281A1 (en) 1999-12-06 2000-12-06 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Publications (2)

Publication Number Publication Date
AU2134001A AU2134001A (en) 2001-06-18
AU784630B2 true AU784630B2 (en) 2006-05-18

Family

ID=23808998

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21340/01A Ceased AU784630B2 (en) 1999-12-06 2000-12-06 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Country Status (12)

Country Link
US (1) US7442763B2 (https=)
EP (1) EP1244693B1 (https=)
JP (1) JP2003516417A (https=)
AT (1) ATE298346T1 (https=)
AU (1) AU784630B2 (https=)
CA (1) CA2396739A1 (https=)
DE (1) DE60020997T2 (https=)
ES (1) ES2246915T3 (https=)
MX (1) MXPA02005626A (https=)
NZ (1) NZ520762A (https=)
WO (1) WO2001042281A1 (https=)
ZA (1) ZA200205795B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
ATE298346T1 (de) 1999-12-06 2005-07-15 Chu Sainte Justine Verbindungen zur behandlung von abnormaler glomerularer filtration, patent ductus arteriosus und osteoporosis
EP1467738A1 (en) * 2001-10-08 2004-10-20 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
US20050059742A1 (en) * 2001-10-31 2005-03-17 Jabbour Henry Nicolas Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia
US7414029B2 (en) 2002-05-23 2008-08-19 Theratechnologies, Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
EP1878741A3 (en) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
JP2006506327A (ja) * 2002-05-23 2006-02-23 セラテクノロジーズ インコーポレイティド プロスタグランジンｅ２の受容体サブタイプｅｐ４のアンタゴニスト・ポリペプチド
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
EP2846793A1 (en) 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens
WO1997018236A1 (en) * 1995-11-13 1997-05-22 The Research Foundation Of State University Of New York MIMOTOPES AND ANTI-MIMOTOPES OF HUMAN PLATELET GLYCOPROTEIN Ib/IX
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
US5508384A (en) * 1992-09-10 1996-04-16 New York University Polypeptide derived from a popamine receptor, and compositions and methods thereof
CN1118572A (zh) * 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
US5869281A (en) 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
JPH09504174A (ja) * 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
WO1996006856A1 (en) * 1994-08-31 1996-03-07 Robert Webber Dopamine receptor peptides and anti-peptide antibodies
EP2301562B1 (en) * 1994-12-12 2013-04-17 Omeros Corporation Irrigation solution and method for inhibition of pain, inflammation and spasm
NZ302524A (en) 1995-01-25 1999-05-28 Cor Therapeutics Inc Dna encoding the c140 receptor, agonists and antagonists therefor and use in assays to detect vascular pressure abnormalities
US6117839A (en) * 1995-06-07 2000-09-12 Gensci Regeneration Sciences, Inc. Bone stimulating factor
WO1998010651A1 (en) * 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5955575A (en) * 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
AUPP320998A0 (en) * 1998-04-27 1998-05-21 Walter And Eliza Hall Institute Of Medical Research, The Tyrosine phosphatase IA-2 T-cell epitopes
US6984719B1 (en) * 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
ATE298346T1 (de) 1999-12-06 2005-07-15 Chu Sainte Justine Verbindungen zur behandlung von abnormaler glomerularer filtration, patent ductus arteriosus und osteoporosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens
WO1997018236A1 (en) * 1995-11-13 1997-05-22 The Research Foundation Of State University Of New York MIMOTOPES AND ANTI-MIMOTOPES OF HUMAN PLATELET GLYCOPROTEIN Ib/IX
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses

Also Published As

Publication number Publication date
DE60020997T2 (de) 2006-05-24
AU2134001A (en) 2001-06-18
ES2246915T3 (es) 2006-03-01
NZ520762A (en) 2005-02-25
ATE298346T1 (de) 2005-07-15
WO2001042281A1 (en) 2001-06-14
US20030017988A1 (en) 2003-01-23
DE60020997D1 (de) 2005-07-28
EP1244693B1 (en) 2005-06-22
JP2003516417A (ja) 2003-05-13
US7442763B2 (en) 2008-10-28
MXPA02005626A (es) 2004-09-10
CA2396739A1 (en) 2001-06-14
EP1244693A1 (en) 2002-10-02
ZA200205795B (en) 2007-01-31

Similar Documents

Publication Publication Date Title
US7943728B2 (en) Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
JP4786047B2 (ja) ペプチド誘導体
AU784630B2 (en) Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis
JPH10506608A (ja) 白血球接着のインヒビター
EP0669978A1 (en) Flk-1 is a receptor for vascular endothelial growth factor
KR20230036156A (ko) α4β7 인테그린 티오에테르 펩티드 길항제
US20040023853A1 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
JP2006506327A5 (https=)
ES2393462T3 (es) Péptido útil para inhibir la actividad del receptor de prosta-glandina F2X
BR112019018197A2 (pt) composições e métodos para melhorar a função sexual
US20230391826A1 (en) Compositions and methods for treating diseases
AU701677B2 (en) Recombinant C140 receptor and its agonists and antagonists
US20130005944A1 (en) CXCR4 Receptor Compounds
WO1997011091A1 (fr) Nouveaux composes peptidiques et leurs compositions medicinales
WO2001089582A1 (en) Preventives and remedies for pulmonary hypertension
JP2003516417A5 (https=)
CA2689373A1 (en) G protein-coupled receptor antagonists
JP2008013436A (ja) 血管形成促進剤
AU777634B2 (en) Methods of inhibiting osteoclastogenesis
US7414029B2 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
KR20250011895A (ko) 유로키나제-유형 플라스미노겐 활성화제 수용체 결합 펩타이드 및 사용 방법
JPH10271997A (ja) 新規Ｆａｓリガンド様タンパク質およびそのＤＮＡ
WO2020000063A1 (en) Rheumatoid arthritis treatment
JP2002047203A (ja) 肺高血圧症予防・治療剤
EP1878741A2 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 20020906